Effectiveness of antibiotic combination therapy in patients with active ulcerative colitis: A randomized, controlled pilot trial with long-term follow-up

Scandinavian Journal of Gastroenterology

Volumn 40, Issue 11, 2005, Pages 1334-1342

  Ohkusa, Toshifumi ^a   Nomura, Tetsuya ^a   Terai, Takeshi ^a   Miwa, Hiroto ^a   Kobayashi, Osamu ^a   Hojo, Mariko ^a   Takei, Yoshiyuki ^a   Ogihara, Tatsuo ^a   Hirai, Shu ^a   Okayasu, Isao ^b   Sato, Nobuhiro ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Antibiotics combination therapy; Fusobacterium varium; Mucosa associated bacteria; Ulcerative colitis

Indexed keywords

AMOXICILLIN; AMPICILLIN; ANTIBIOTIC AGENT; CEFAZOLIN; CEFTAZIDIME; CHLORAMPHENICOL; CIPROFLOXACIN; CLARITHROMYCIN; CLINDAMYCIN; FOSFOMYCIN; GENTAMICIN; IMIPENEM; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; MESALAZINE; METRONIDAZOLE; OFLOXACIN; PENICILLIN DERIVATIVE; PLACEBO; PREDNISOLONE; PROBIOTIC AGENT; PROTON PUMP INHIBITOR; SALAZOSULFAPYRIDINE; STEROID; TETRACYCLINE; TOBRAMYCIN; VANCOMYCIN;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COLITIS; COLON BIOPSY; COLON MUCOSA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE ACTIVITY; DRUG EFFICACY; FEMALE; FEVER; FOLLOW UP; FUSOBACTERIUM VARIUM; GASTROINTESTINAL ENDOSCOPY; HISTOPATHOLOGY; HUMAN; MALAISE; MALE; MINIMUM INHIBITORY CONCENTRATION; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SYMPTOMATOLOGY; TASTE DISORDER; TREATMENT OUTCOME; ULCERATIVE COLITIS; URTICARIA;

ADOLESCENT; ADULT; AMOXICILLIN; ANTI-BACTERIAL AGENTS; COLITIS, ULCERATIVE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; FUSOBACTERIUM; FUSOBACTERIUM INFECTIONS; HUMANS; MALE; METRONIDAZOLE; MIDDLE AGED; PROBABILITY; REFERENCE VALUES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; TETRACYCLINE; TREATMENT OUTCOME;

EID: 27844480083     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.1080/00365520510023648     Document Type: Article

References (30)

1. Sartor RB. Intestinal microflora in human and experimental inflammatory bowel disease. Curr Opin Gastroenterol 2001;17:324-30.
2. Sartor RB. How relevant to human inflammatory bowel disease are current animal models of intestinal inflammation? [review]. Aliment Pharmacol Ther 1997;11 Supply 3:89-96.
3. Sartor RB. Role of the enteric microflora in the pathogenesis of intestinal inflammation and arthritis [review]. Aliment Pharmacol Ther 1997;11 Suppl 3:17-22.
4. 2 microglobulin transgenic rats. J Clin Invest 1996;98:945-53.
5. Robert A, Asano T. Resistance of germfree rats to indomethacin-induced intestinal lesions. Prostaglandins 1977;14:333-41.
6. Panwala CM, Jones JC, Viney JL. A novel model of inflammatory bowel disease: mice deficient for the multiple drug resistance gene, mdr1a, spontaneously develop colitis. J Immunol 1998;161:5733-44.
7. Sadlack B, Merz H, Schorle H, Schimpl A, Feller AC, Horak I. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell 1993;75:253-61.
8. Sellon RK, Tonkonogy S, Schultz M, Dieleman LA, Grenther W, Balish E, et al. Resident enteric flora are necessary for development of spontaneous colitis and immune system activation in IL-10- deficient mice. Infect Immun 1998;66:5224-31.
9. Dianda L, Hanby AM, Wright NA, Sebesteny A, Hayday AC, Owen MJ. T cell receptor-alpha beta-deficient mice fail to develop colitis in the absence of a microbial environment. Am J Pathol 1997;150:91-7.
10. Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001;411:603-6.
11. Agnese DM, Calvano JE, Hahm SJ, Coyle SM, Corbett SA, Calvano SE, et al. Human toll-like receptor 4 mutations but not CD14 polymorphisms are associated with an increased risk of gram-negative infections. J Infect Dis 2002;186:1522-5.
12. Hanauer SB. Medical therapy of ulcerative colitis. Lancet 1993;14:342:412-7.
13. Farrell RJ, Peppercorn MA. Ulcerative colitis. Lancet 2002;359:331-40.
14. Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002;347:417-29.
15. Ohkusa T, Okayasu I, Ogihara T, Morita K, Ogawa M, Sato N. Induction of experimental ulcerative colitis by Fusobacterium varium isolated from colonic mucosa of patients with ulcerative colitis. Gut 2003;52:79-83.
16. Ohkusa T, Sato N, Ogihara T, Morita K, Ogawa M, Okayasu I. Fusobacterium varium localized in the colonic mucosa of patients with ulcerative colitis stimulates species-specific antibody. J Gastroenterol Hepatol 2002;17:849-53.
17. Matts SGF. The value of rectal biopsy in the diagnosis of ulcerative colitis. Quart J Med 1961;120:393-407.
18. Lichtiger S, Present DH, Kornbluth A, Gelernt I, Bauer J, Galler G, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994;330:1841-5.
19. Hsu SM, Raine L, Fanger H. The use of antiavidin antibody and avidin-biotin-peroxidase complex in immunoperoxidase technics. Am J Clin Pathol 1981;75:816-21.
20. Truelove SC, Jewell DP. Intensive intravenous regimen for severe attacks of ulcerative colitis. Lancet 1974;1:1067-70.
21. Dickinson RJ, O'Connor HJ, Pinder I, Hamilton I, Johnston D, Axon AT. Double-blind controlled trial of oral vancomycin as adjunctive treatment in acute exacerbations of idiopathic colitis. Gut 1985;26:1380-4.
22. Chapman RW, Selby WS, Jewell DP. Controlled trial of intravenous metronidazole as an adjunct to corticosteroids in severe ulcerative colitis. Gut 1986;27:1210-2.
23. Burke DA, Axon AT, Clayden SA, Dixon MF, Johnston D, Lacey RW. The efficacy of tobramycin in the treatment of ulcerative colitis. Aliment Pharmacol Ther 1990;4:123-9.
24. Lobo AJ, Burke DA, Sobala GM, Axon AT. Oral tobramycin in ulcerative colitis: effect on maintenance of remission. Aliment Pharmacol Ther 1993;7:155-8.
25. Mantzaris GJ, Hatzis A, Kontogiannis P, Triadaphyllou G. Intravenous tobramycin and metronidazole as an adjunct to corticosteroids in acute, severe ulcerative colitis. Am J Gastroenterol 1994;89:43-6.
26. Mantzaris GJ, Archavlis E, Christoforidis P, Kourtessas D, Amberiadis P, Florakis N, et al. A prospective randomized controlled trial of oral ciprofloxacin in acute ulcerative colitis. Am J Gastroenterol 1997;92:454-6.
27. Turunen UM, Farkkila MA, Hakala K, Seppala K, Sivonen A, Ogren M, et al. Long-term treatment of ulcerative colitis with ciprofloxacin: a prospective, double-blind, placebo-controlled study. Gastroenterology 1998;115:1072-8.
28. Gionchetti P, Rizzello F, Ferrieri A, Venturi A, Brignola C, Ferretti M, et al. Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroid treatment: a double-blind, placebo-controlled trial. Dig Dis Sci 1999;44:1220-1.
29. Raleigh J. Chemotherapy of tuberculosis. In: Kubica G, Wayne L, editors. Mycobacteria: a source book, vol. 15. New York: Marcel Dekker; 1984. pp 1007-20.
30. Unge P. What other regimens are under investigation to treat Helicobacter pylori infection? Gastroenterology 1997;113: S131-S48.